K. Klein

发表

Polymeric penetration enhancers promote humoral immune responses to mucosal vaccines.

R. Shattock, K. Klein, Jamie F S Mann, 2014, Journal of controlled release : official journal of the Controlled Release Society.

Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques

Jerome H. Kim, B. Korber, H. Liao, 2015, PLoS pathogens.

Deep Gene Sequence Cluster Analyses of Multi-Virus-Infected Mucosal Tissue Reveal Enhanced Transmission of Acute HIV-1

J. Bailey, T. Hope, Yong Gao, 2020, Journal of Virology.

Investigation of magnetically driven passage of magnetic nanoparticles through eye tissues for magnetic drug targeting

F. Wiekhorst, K. Klein, S. Dutz, 2020, Nanotechnology.

A “Prime-Pull” Vaccine Strategy Has a Modest Effect on Local and Systemic Antibody Responses to HIV gp140 in Mice

R. Shattock, K. Klein, J. Tregoning, 2013, PloS one.

Evaluation of mucosal adjuvants and immunization routes for the induction of systemic and mucosal humoral immune responses in macaques

R. Veazey, R. Shattock, K. Klein, 2015, Human vaccines & immunotherapeutics.

Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice

R. Shattock, K. Klein, V. Buffa, 2012, PloS one.

Blocking T‐cell egress with FTY720 extends DNA vaccine expression but reduces immunogenicity

P. McKay, R. Shattock, K. Klein, 2021, Immunology.

Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen☆

R. Shattock, K. Klein, Jamie F S Mann, 2012, Journal of controlled release : official journal of the Controlled Release Society.

Higher sequence diversity in the vaginal tract than in blood at early HIV-1 infection

C. Morrison, Pai-Lien Chen, C. Kwok, 2018, PLoS pathogens.

An in vitro Model to Mimic Selection of Replication-Competent HIV-1 Intersubtype Recombination in Dual or Superinfected Patients.

Yong Gao, E. Arts, K. Klein, 2017, Journal of molecular biology.

Characterization of a plant-produced recombinant human secretory IgA with broad neutralizing activity against HIV

M. Paul, R. Reljic, C. V. van Dolleweerd, 2014, mAbs.

First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses

Yong Gao, E. Arts, Shilei Ding, 2016, Retrovirology.

Neutralizing IgG at the Portal of Infection Mediates Protection against Vaginal Simian/Human Immunodeficiency Virus Challenge

P. Hraber, H. Liao, B. Haynes, 2013, Journal of Virology.

Eradication of HIV-1 latent reservoirs through therapeutic vaccination

K. Klein, Jamie F S Mann, J. Pankrac, 2017, AIDS Research and Therapy.

Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection

P. McKay, R. Shattock, K. Klein, 2013, Journal of controlled release : official journal of the Controlled Release Society.

A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system

Yong Gao, E. Arts, P. McKay, 2018, npj Vaccines.

Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010

P. Palma, M. V. van Gils, Sarah Brinckmann, 2010, Journal of Translational Medicine.

Aggregate complexes of HIV-1 induced by multimeric antibodies

Jerome H. Kim, B. Haynes, D. Montefiori, 2014, Retrovirology.

Discrete partitioning of HIV-1 Env forms revealed by viral capture

P. McKay, R. Shattock, K. Klein, 2015, Retrovirology.

A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system

Yong Gao, E. Arts, P. McKay, 2018, npj Vaccines.

Enhanced Immunogenicity of an HIV-1 DNA Vaccine Delivered with Electroporation via Combined Intramuscular and Intradermal Routes

P. McKay, R. Shattock, K. Klein, 2014, Journal of Virology.

Enhanced immunogenicity of a HIV-1 DNA vaccine delivered with electroporation via

P. McKay, R. Shattock, K. Klein, 2014 .

Correction: Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference

P. Palma, P. Selhorst, M. V. van Gils, 2010, Journal of Translational Medicine.

Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference

P. Palma, P. Selhorst, M. V. van Gils, 2010, Journal of Translational Medicine.

Discrete partitioning of HIV-1 Env forms revealed by viral capture

P. McKay, R. Shattock, K. Klein, 2015, Retrovirology.

Characterization of VRC01, a potent and broadly neutralizing anti‐HIV mAb, produced in transiently and stably transformed tobacco

J. Ma, D. Maresch, K. Klein, 2013, Plant biotechnology journal.

A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection

Yong Gao, E. Arts, A. Poon, 2020, EBioMedicine.

First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses

Eric J. Arts, Stefan Schneider, Yong Gao, 2016, Retrovirology.

Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen☆

P. McKay, K. Klein, Jamie F S Mann, 2012, Journal of controlled release : official journal of the Controlled Release Society.

Polymeric penetration enhancers promote humoral immune responses to mucosal vaccines.

R. Shattock, K. Klein, Jamie F S Mann, 2014, Journal of controlled release : official journal of the Controlled Release Society.